Inhibrx
Inhibrx is a clinical-stage biotechnology company developing biologic therapeutics for life-threatening conditions using a proprietary single-domain antibody platform.
Services
Inhibrx is a clinical-stage biotechnology company focused on developing biologic therapeutics for life-threatening conditions. The company utilizes a proprietary single-domain antibody (sdAb) platform aimed at addressing complex target biology. Its therapeutic pipeline includes candidates that target specific diseases such as Alpha-1 Antitrypsin Deficiency (AATD) and cancers requiring tumor-selective programmed cell death. Inhibrx engages in collaborations to further its research and development efforts, including partnerships for developing chimeric antigen receptor (CAR) T-cell therapies.
Products
Inhibrx's pipeline includes four differentiated clinical-stage biologic therapeutic candidates. INBRX-101 is designed for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). INBRX-109 is a tetravalent DR5 agonist aimed at inducing tumor-selective programmed cell death. INBRX-106 targets OX40 to promote T-cell expansion and enhanced effector function. These products are developed using Inhibrx's proprietary single-domain antibody (sdAb) platform, which aims to address complex biological targets effectively.
Collaborations
Inhibrx collaborates with 2seventy bio (formerly bluebird bio) on developing chimeric antigen receptor (CAR) T-cell therapies. The company also has an exclusive license agreement with Elpiscience for the development and commercialization of INBRX-106 in Greater China. These collaborations help Inhibrx extend its innovative approaches and leverage external expertise and capabilities in biotechnology research and development.
Stock Information
Inhibrx trades on the NASDAQ Global Market under the stock symbol INBX. The company went public on August 19, 2020. As a policy, Inhibrx does not expect to declare or pay any cash or other dividends on its common stock. The company's fiscal year ends on December 31st. This information is relevant for investors and stakeholders looking for financial data or considering an investment in Inhibrx.
Headquarters and Location
Inhibrx is headquartered at Torrey Pines Science Park, 11025 N Torrey Pines Rd #200, La Jolla, CA 92037. The company emphasizes a collaborative and cross-disciplinary approach to its research and development activities. Nestled in San Diego, California, the location offers a conducive environment for scientific innovation and collaboration within the biotechnology sector.